ArticleInfection and drug resistance2025
Superiority of TB-PCR Over Conventional and Immunologic Tests for Diagnosing Tuberculosis in Small Bronchoscopic Non-Malignant Specimens.
Article in Infection and drug resistance, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In the small non-malignant specimens acquired through respiratory endoscopy, the conventional pathological examination approaches such as acid-fast staining have certain restrictions in the sensitivity of tuberculosis diagnosis. Objective: To investigate the sensitizing effect and clinical value of polymerase chain reaction for Mycobacterium tuberculosis (TB-PCR) based on fluorescent probe nucleic acid detection technology in improving the diagnostic positive rate of non-malignant small specimens obtained by respiratory endoscopy. Methods: A retrospective analysis was conducted on 729 patients with suspected TB who underwent respiratory endoscopy. All patients provided small non-malignant specimens for TB-PCR, acid-fast staining, and mycobacterial culture. A clinical composite diagnosis served as the gold standard. Diagnostic performance was assessed by accuracy, sensitivity, specificity, and area under the ROC curve (AUC). A subgroup of 113 patients underwent additional testing (T-SPOT. TB, TB-Ab, BALF-G-Xpert, BALF-TB) for extended comparison. Results: The AUC, accuracy, sensitivity, specificity, PPV and NPV of TB-PCR in the diagnosis of TB were 0.88 (95% CI: 0.86-0.90), 0.88 (95% CI: 0.85-0.90), 0.99 (95% CI: 0.98-1.00), 0.78 (0.74-0.82), 0.79 (95% CI: 0.75-0.83), 0.99 (95% CI: 0.97-1.00), respectively. Among 729 patients (391 TB+, 338 TB-), TB-PCR showed significantly higher overall diagnostic efficacy (AUC: 0.88) than acid-fast staining (AUC: 0.77, P<0.05) and was comparable to culture (AUC: 0.87). TB-PCR also demonstrated superior accuracy (0.89 vs 0.61-0.85, P<0.05) compared to immunologic and BALF-based tests in the subgroup analysis, achieving nearly perfect sensitivity (0.99-1.00) and high NPV (0.99-1.00). Conclusion: The application of TB-PCR for the detection of lung samples obtained through respiratory endoscopy holds significant clinical application value in the diagnosis of TB. Clinicians should fully recognize the merits and potential of TB-PCR technology, proactively apply it in clinical practice, and choose appropriate detection methods based on the specific conditions of patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.